Enzo Biochem, Inc.
ENZ was delisted on the 17th of April, 2025.
108 hedge funds and large institutions have $172M invested in Enzo Biochem, Inc. in 2018 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 42 increasing their positions, 32 reducing their positions, and 17 closing their positions.
341% more call options, than puts
Call options by funds: $507K | Put options by funds: $115K
31% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 32
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less funds holding
Funds holding: 116 → 108 (-8)
32% less capital invested
Capital invested by funds: $252M → $172M (-$79.8M)
41% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$4.52M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$1.9M |
| 3 |
EGA
Evermore Global Advisors
Summit,
New Jersey
|
+$1.66M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.52M |
| 5 |
Millennium Management
New York
|
+$1.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$2.82M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$2.59M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$2.34M |
| 4 |
MCM
McKinley Capital Management
Anchorage,
Alaska
|
-$1.46M |
| 5 |
MAG
Millrace Asset Group
Berwyn,
Pennsylvania
|
-$1.39M |
ENZ Hedge Fund Activity: Q1 2018 in Review
108 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Enzo Biochem, Inc. (ENZ) for Q1 2018, worth a combined $172M — down 32% from $252M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of ENZ and 10 opened new positions — a net loss of 7 holders — while 32 trimmed existing stakes and 42 added.
The largest buyer was Renaissance Technologies, adding an estimated $4.52M. The largest seller was Panagora Asset Management, cutting an estimated $2.82M.
- 108 institutional investors held Enzo Biochem, Inc. (ENZ) as of Q1 2018, down from 116 in Q4 2017.
- Funds reported $172M of Enzo Biochem, Inc. stock for Q1 2018, down 32% quarter-over-quarter.
- 10 funds opened new Enzo Biochem, Inc. positions in Q1 2018 and 17 closed out, a net change of -7 holders.
- The largest Enzo Biochem, Inc. buyer in Q1 2018 was Renaissance Technologies, an estimated $4.52M added.
- The largest Enzo Biochem, Inc. seller in Q1 2018 was Panagora Asset Management, an estimated $2.82M sold.
Based on aggregated 13F filings for Q1 2018.